Advancements in technology transfer to a Contract Development and Manufacturing Organization

In a recent interview with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London, Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, discussed the challenges associated with technology transfer in the cell and gene therapy industry. He shared his insights on the complexities involved in transferring technology from development to GMP manufacturing, as well as from a customer to a contract development and manufacturing organization (CDMO).

Roberto highlighted the critical timelines that present the biggest challenges in the field of technology transfer. He explained how balancing the number of batches that need to be manufactured is essential to ensuring sufficient and scientifically quality data within these timelines.

During his conversation with Caroline Peachey, Roberto also shared his insights on the technology and manufacturing trends and priorities that he foresees for the cell and gene therapy industry in 2024. He delved into the nuances of technology transfer and its implications for the industry.

By Samantha Johnson

As a content writer at, I craft engaging and informative articles that aim to captivate readers and provide them with valuable insights. With a background in journalism and a passion for storytelling, I thoroughly enjoy delving into diverse topics, conducting research, and producing compelling content that resonates with our audience. From breaking news pieces to in-depth features, I strive to deliver content that is both accurate and engaging, constantly seeking to bring fresh perspectives to our readers. Collaborating with a talented team of editors and journalists, I am committed to maintaining the high standards of journalism upheld by our publication.

Leave a Reply